SurVaxM is under clinical development by MimiVax and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SurVaxM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SurVaxM overview
SurVaxM is under development for the treatment of glioblastoma, brain cancer, recurrent gioblastoma, high grade glioma, multiple myeloma, neuroendocrine tumors including neuroendocrine gastroenteropancreatic tumors and pediatric medulloblastoma, glioblastoma multiforme, anaplastic astrocytoma, high-grade astrocytoma, anaplastic oligodendroglioma, anaplastic ependymoma, ependymoma and diffuse intrinsic pontine gliomas. The vaccine candidate is administered through subcutaneously. SVN53-67/M57-KLH is a peptide vaccine containing a 15-mer peptide with C to M modification at the amino acid position 57. It is derived from the anti-apoptosis protein survivin. It is conjugated with keyhole limpet hemocyanin (KLH).
It was under development for the treatment of autoimmune diseases.
MimiVax overview
MimiVax operates as a pharmaceutical company that discovers and develops immunotherapeutic vaccines and targeted therapies for the treatment of cancer. It’s lead candidate is SurVaxM. Its SurVaxM is a cancer vaccine that stimulates a potent immune response and the survivin molecule and an important cellular protein that sustains the viability of tumor cells and can be delivered through a simple injection. MimiVax’s SurVaxM is under clinical trials in recurrent glioma and newly diagnosed glioblastoma; prolongs survival in pre-clinical models of ovarian, brain, renal and prostate cancers. survivin is a cell-survival protein that is present in most cancer and rarely detectable in normal tissue and immunotherapeutic vaccine demonstrate safety and tolerability in a phase. MimiVax is headquartered in Buffalo, New York, the US.
For a complete picture of SurVaxM’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
